SK Bioscience and IDT Join BARDA–IAVI Bundibugyo Project: Fact-Check and Key Points for the November 5 Q3 IR Call

Images used in this article are not official company images.

SK Bioscience (302440) and its German subsidiary IDT Biologika are participating in a U.S. government-funded project to develop a vaccine against the Bundibugyo Ebola virus.

On October 28, 2026, the International AIDS Vaccine Initiative (IAVI) announced that it had entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, providing an initial $36 million in funding. The contract has a maximum value of $99 million.

However, the $99 million represents the maximum value of the contract between BARDA and IAVI. It does not mean that SK Bioscience or IDT Biologika has been awarded that amount. The amounts actually allocated to the two companies have not been disclosed.

This project is an international collaboration linking vaccine development with manufacturing capabilities. In particular, SK Bioscience’s role in scaling up production is contingent on the exercise of an option, making it important to distinguish project participation from the potential generation of actual revenue.

Meanwhile, SK Bioscience is scheduled to hold a conference call at 4:00 p.m. on November 5 to announce its third-quarter 2026 financial results and provide a business update. This article outlines the contractual structure of the BARDA–IAVI project, the roles of participating organizations, and potential points of interest for the third-quarter earnings announcement based on publicly available information.

1. BARDA Provides IAVI With an Initial $36 Million

According to IAVI’s October 28 announcement, BARDA entered into a contract with IAVI to support development of a vaccine against Bundibugyo virus (BDBV).

The key contract details are as follows.

The most important distinction in this contract is between the initial funding amount and the contract ceiling.

The initial $36 million represents the starting funding commitment under IAVI’s contract with BARDA. The maximum of $99 million is the contractual ceiling and does not mean that the entire amount will be paid or that all subsequent activities have been authorized.

BARDA and IAVI are also the contracting parties. Although SK Bioscience and IDT Biologika are project participants, the currently available disclosures do not establish their individual contract values or revenue-sharing arrangements.

It would therefore be inaccurate to describe this announcement as ‘a $99 million contract awarded to SK Bioscience’ or ‘immediately confirmed new revenue’.

2. Roles of Participating Organizations: SK to Scale Up Production, IDT to Handle Fill-Finish

IAVI oversees the overall project, while multiple institutions and companies share responsibilities for development, manufacturing, and technical support.

The publicly disclosed roles are summarized below.

SK Bioscience: Production Scale-Up

SK Bioscience is participating in a role that would involve scaling up vaccine production if a subsequent option is exercised.

Production scale-up involves expanding manufacturing processes and systems from the volumes required for research and development or early clinical trials to accommodate larger-scale manufacturing.

However, this announcement alone does not establish specific production volumes, facility utilization plans, or a production start date for SK Bioscience.

The condition that the option must be exercised is particularly important. Production-related activities may expand as the project progresses, but it cannot currently be concluded that all such activities have been confirmed or recognized as revenue.

IDT Biologika: Fill-Finish Manufacturing for Vaccine Stockpiles

IDT Biologika, SK Bioscience’s German subsidiary, is responsible for fill-finish manufacturing of vaccines intended for stockpiling.

Fill-finish is the manufacturing stage in which bulk vaccine product is filled into final containers and completed as a finished product.

IDT’s role in this project is connected to the manufacturing system intended to support future vaccine stockpiling.

However, actual fill-finish volumes, supply schedules, and contract values have not been disclosed. It is therefore difficult to translate IDT’s participation directly into confirmed revenue or operating profit for any particular quarter.

Roles of Hilleman Laboratories and MSD

Hilleman Laboratories is responsible for manufacturing initial clinical-trial vaccine supplies and would also participate in technology transfer if a subsequent option is exercised.

MSD provides technical support related to vaccine manufacturing.

Rather than assigning all vaccine development and manufacturing activities to a single company, the project is structured around collaboration between companies with relevant technologies and those with manufacturing capabilities at different stages.

3. Why a Bundibugyo Virus Vaccine Is Needed

Bundibugyo virus is one of the viruses that cause Ebola disease.

Even where vaccine technologies against Ebola already exist, a vaccine targeting one virus cannot automatically be assumed to provide protection against another. Developing a separate vaccine targeting Bundibugyo virus is therefore necessary.

According to information presented by IAVI, the relevant cumulative outbreak figures for the Democratic Republic of the Congo (DRC) as of October 25, 2026, were as follows.

• Confirmed cases: 10,060
• Deaths: 4,887

These figures were cited in IAVI’s announcement and do not represent patients protected or treated through the new BARDA contract. They also must not be interpreted as the number of confirmed cases and deaths attributable to a single Bundibugyo virus outbreak.

The project focuses on leveraging existing Ebola-response technologies while developing a vaccine against Bundibugyo virus and establishing a foundation for future manufacturing.

Development Stage: Efficacy in Humans Has Not Been Demonstrated

Publicly available materials refer to a development plan that includes efficacy evaluation in nonhuman primates and a Phase 1 clinical trial.

However, findings in nonhuman primates cannot automatically be interpreted as evidence of protective efficacy in humans.

Human clinical evaluation and assessment of its results remain future steps.

Accordingly, the signing of this contract does not mean that clinical success, regulatory approval, or commercialization of the vaccine has been confirmed.

Even as vaccine development proceeds, uncertainties remain regarding clinical trial outcomes, further development, and manufacturing preparations.

4. Relationship With the CEPI-Supported Project

The BARDA–IAVI project also complements Bundibugyo virus vaccine-related activities supported by the Coalition for Epidemic Preparedness Innovations (CEPI).

An important aspect is the use of existing vaccine manufacturing processes and technologies.

Hilleman Laboratories plans to apply an improved manufacturing process associated with MSD’s Zaire Ebola vaccine, which has received World Health Organization prequalification (WHO-PQ).

This approach seeks to build a foundation for Bundibugyo virus vaccine development and manufacturing by drawing on existing experience and process technologies used for the Zaire Ebola vaccine.

However, the Zaire Ebola vaccine and the Bundibugyo virus vaccine target different viruses. The WHO-PQ status of the existing vaccine does not guarantee approval or efficacy of the vaccine being developed under this project.

SK Bioscience’s participation can also be understood in the context of linking existing international vaccine collaborations with manufacturing technologies.

However, currently available information does not substantiate a specific historical claim such as ‘SK Bioscience participated in CEPI’s Zaire Ebola project in January 2026’.

What has been confirmed is that SK Bioscience and IDT Biologika are participating in the current BARDA–IAVI project in production scale-up and fill-finish roles, respectively.

5. Financial Implications: Project Participation Is Not the Same as Revenue Recognition

The most important consideration when interpreting the financial implications of this announcement is the distinction between contract value and actual revenue.

The following facts can be established from currently available information.

• BARDA and IAVI entered into a contract with an initial value of $36 million and a maximum value of $99 million.
• SK Bioscience is participating in a production scale-up role, contingent on the exercise of an option.
• IDT Biologika is participating in a fill-finish role for vaccines intended for stockpiling.
• The individual allocations and specific revenue arrangements for SK Bioscience and IDT have not been disclosed.

Consequently, the full BARDA contract value cannot be directly included in SK Bioscience’s projected revenue.

In particular, the initial contract funding is allocated to IAVI. The extent to which SK Bioscience and IDT may enter into separate contracts or recognize revenue remains to be established independently.

Without confirmation of option exercise, production schedules, and conditions for actual delivery or service provision, it is difficult to estimate the timing and amount of future revenue.

The significance of this project lies less in currently confirmed financial results than in the roles the two companies may perform within an international vaccine development and manufacturing partnership.

However, the extent to which their participation will contribute to actual financial performance depends on subsequent contracts and project progress.

6. SK Bioscience’s November 5 Third-Quarter Conference Call

SK Bioscience is scheduled to hold a conference call at 4:00 p.m. on November 5, 2026.

According to the October 26 regulatory filing and related reports, the main details are as follows.

The stated purpose in the filing is to announce third-quarter financial results and provide a business update.

There is therefore no basis for concluding that the conference call has been specifically scheduled to disclose the BARDA project’s contract value or changes to the company’s full-year earnings outlook.

Nevertheless, because the project was announced on October 28, related questions may arise during the conference call.

7. Five Potential Focus Areas for November 5

The following are potential areas of interest based on currently available public information. The company has not confirmed that it will present or address these specific topics.

① Third-Quarter Consolidated and Separate Results and IDT’s Contribution

The first area is revenue and operating profit or loss for the third quarter of 2026.

Because SK Bioscience’s consolidated results include those of its subsidiary IDT Biologika, it is important to distinguish consolidated results from the parent company’s separate financial results.

Of particular interest is how IDT’s revenue contribution and profit structure affected consolidated performance.

Beyond whether consolidated revenue increased, the differences between separate and consolidated performance may help clarify the sources of the changes.

② Whether Vaccine Shipment Deferrals Mentioned in the First Half Were Reflected in Q3

The second area concerns vaccine shipment deferrals discussed in the company’s first-half earnings commentary.

If revenue recognition for certain volumes was shifted to a later period, an important question is whether those volumes were actually recognized in the third quarter.

However, previous references to deferred volumes do not, by themselves, establish that the associated revenue was recognized in Q3.

Actual recognition and amounts would need to be established from the third-quarter earnings materials or the company’s explanations.

③ Updates on the Phase 3 Trial of PCV21 (GBP410)

The third area is progress in the Phase 3 clinical trial of the 21-valent pneumococcal conjugate vaccine (PCV21, GBP410).

Additional information about clinical development progress or timelines may be of interest during the conference call, but the IR filing does not separately confirm this topic as a scheduled announcement.

New clinical results or changes to development timelines therefore cannot be assumed in advance.

If the company discusses the program, the relevant distinction will be between previously disclosed timelines and any newly confirmed information.

④ Whether the BARDA–IAVI Project Is Discussed

The fourth area concerns the Bundibugyo virus vaccine project itself.

Because the project was announced on October 28, after the third quarter had ended, the announcement itself should not be directly linked to confirmed third-quarter revenue.

Even if related questions arise during the conference call, it remains unconfirmed whether the company will disclose specific contract values or production schedules.

Because SK Bioscience’s role is contingent on option exercise, the eventual scope of its activities is particularly important.

Similarly, the disclosure of IDT’s fill-finish role alone is insufficient to estimate revenue.

⑤ Potential Changes to Full-Year Guidance

The fifth area is the company’s explanation of its full-year earnings outlook.

The currently disclosed purpose of the conference call is to announce third-quarter 2026 results and provide a business update. A formal upward revision to full-year guidance is not separately specified in the filing.

Participation in the BARDA–IAVI contract alone also does not establish that SK Bioscience’s full-year revenue or operating profit outlook will be raised.

If the outlook changes, the specific figures and supporting explanations released by the company will be necessary to establish the revision.

8. Summary: International Vaccine Manufacturing Collaboration and Near-Term Earnings Should Be Distinguished

The confirmed fact about the BARDA–IAVI project is that SK Bioscience and IDT Biologika are participating in a collaborative framework for developing and manufacturing a Bundibugyo virus vaccine.

SK Bioscience is assigned a production scale-up role if an option is exercised, while IDT Biologika is responsible for fill-finish manufacturing of vaccines intended for stockpiling.

This is an example of how the two companies’ manufacturing capabilities may be utilized in an international vaccine development project.

However, the $99 million total contract ceiling applies to the agreement between IAVI and BARDA; it is not an amount awarded to SK Bioscience or IDT. The amounts allocated to the companies and the timing of actual revenue generation also remain undisclosed.

The November 5 conference call is expected to provide an opportunity to review third-quarter consolidated and separate results, IDT’s contribution, whether revenue from existing vaccine operations has been recognized, and explanations regarding major development programs.

The BARDA project may be discussed, but without additional disclosures on individual contract values or option exercise, it will be difficult to translate participation into near-term financial figures.

Ultimately, the project announcement and third-quarter earnings report should be evaluated separately. Participation in international collaboration is confirmed, but its specific financial contribution cannot yet be determined without further disclosures.

This article is an informational summary based on materials publicly available through October 29, 2026. It does not constitute investment advice or a recommendation to buy or sell any security. Future business developments and financial performance should be assessed based on the company’s official announcements and regulatory filings.

Sources

• IAVI, IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development, October 28, 2026
• Press9, reporting on SK Bioscience and IDT
• MedicoPharma, reporting on BARDA–IAVI vaccine development collaboration
• Vegan News, reporting on SK Bioscience’s Q3 2026 investor relations presentation